Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry.
We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages.
Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II.
We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics.
We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development.
Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CDRx™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™).
Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.
Why choose Fusion Antibodies?
|
|
 |
Antibody engineering and humanization services Fusion Antibodies offer as a service the humanization of monoclonal antibodies. Contact us to find out more about what Humanization can do for your therapeutic targets. |
 |
No-success no-fee guaranteed antibody sequencing service We are so confident in our Antibody sequencing services, we offer a no-success no-fee guarantee. |
 |
Custom expression and purification of recombinant proteins We are experts at the expression and purification of recombinant proteins from both E. coli and mammalian vectors. We specialize in protein purification using a range of techniques, including purification of insoluble proteins from inclusion bodies. |
 |
Cell line development |